[Special Stock] Biolog, Delta Variant Spreads Again... 99.9% Effective COVID-19 Preventive Emerging

[Asia Economy Reporter Hyungsoo Park] BioLog Devices is showing strong performance. The news that even leading countries in vaccine administration are facing the most severe situation since the COVID-19 outbreak due to the Delta variant appears to have influenced the stock price. Some experts predict that as long as Delta variant infections continue, it will be difficult to achieve herd immunity even with vaccination.

As of 11:22 AM on the 11th, BioLog Devices is trading at 5,520 KRW, up 16.99% from the previous day.

KovixilV, developed by the US company Salbacion, is a spray-type COVID-19 preventive agent. Earlier, on the 3rd, Salbacion announced, "Research results show that KovixilV eliminates 99.99% of the COVID-19 virus," and added, "We are awaiting approval from the FDA and the European Medicines Agency (EMA)." They plan to launch KovixilG, which blocks bacterial and fungal infections, for COVID-19 prevention purposes. Since it is synthesized with the food additive LAE and copper salts in an optimal composition ratio, it is awaiting approval as a medical device rather than a drug.

A representative from Salbacion's domestic investor explained, "Supported by the National Cancer Institute under the US National Institutes of Health (NIH), in vitro and in vivo tests showed that KovixilV eliminates 99.99% of the COVID-19 virus."

Spray-type vaccines and therapeutics have the limitation of shorter efficacy duration compared to intravenous injections. KovixilV is recommended to be sprayed every 6 hours. The product developed by US Salbacion has received GRAS (Generally Recognized As Safe) certification from the US Food and Drug Administration (FDA).

A BioLog Devices representative stated, "If sales approval is obtained around September, we expect KovixilV to become an essential item like masks," adding, "Since COVID-19 does not seem to disappear, using it as a preventive measure provides about 6 hours of effectiveness."

BioLog Devices explained that it invested in Salbacion through its subsidiary. Additionally, it has secured distribution rights for the Middle East region.

This content was produced with the assistance of AI translation services.